AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
All Articles
New Prostate Cancer Data From ASCO 2026: PROTEUS, TALAPRO-3, and Treatment Holidays
By Dalia Hammoud, MD
Together, PROTEUS, TALAPRO-3, and A-DREAM speak to a broader shift in the field: treatment intensity is increasingly being matched to individual risk and response, rather than applied uniformly.
New Prostate Cancer Data From ASCO 2026: PROTEUS, TALAPRO-3, and Treatment Holidays
By Dalia Hammoud, MD
Together, PROTEUS, TALAPRO-3, and A-DREAM speak to a broader shift in the field: treatment intensity is increasingly being matched to individual risk and response, rather than applied uniformly.
New Prostate Cancer Data From ASCO 2026: PROTEUS, TALAPRO-3, and Treatment Holidays
By Dalia Hammoud, MD
Together, PROTEUS, TALAPRO-3, and A-DREAM speak to a broader shift in the field: treatment intensity is increasingly being matched to individual risk and response, rather than applied uniformly.
Practical Updates in Cervical, Ovarian, and Endometrial Cancer From ASCO 2026
By Andrew Emmons Green, MD
Not every practice-relevant finding from the 2026 ASCO Annual Meeting comes from a single blockbuster trial.
Practical Updates in Cervical, Ovarian, and Endometrial Cancer From ASCO 2026
By Andrew Emmons Green, MD
Not every practice-relevant finding from the 2026 ASCO Annual Meeting comes from a single blockbuster trial.
Practical Updates in Cervical, Ovarian, and Endometrial Cancer From ASCO 2026
By Andrew Emmons Green, MD
Not every practice-relevant finding from the 2026 ASCO Annual Meeting comes from a single blockbuster trial.
Bladder Cancer at ASCO 2026: New Standards, Intravesical Approaches, and Enfortumab Vedotin Data
By Rosa M. Nadal Rios, MD, PhD
Bladder cancer management in 2026 has been transformed at multiple stages of disease: in non-muscle invasive disease by the arrival of immune checkpoint inhibitors added to BCG
Bladder Cancer at ASCO 2026: New Standards, Intravesical Approaches, and Enfortumab Vedotin Data
By Rosa M. Nadal Rios, MD, PhD
Bladder cancer management in 2026 has been transformed at multiple stages of disease: in non-muscle invasive disease by the arrival of immune checkpoint inhibitors added to BCG
Bladder Cancer at ASCO 2026: New Standards, Intravesical Approaches, and Enfortumab Vedotin Data
By Rosa M. Nadal Rios, MD, PhD
Bladder cancer management in 2026 has been transformed at multiple stages of disease: in non-muscle invasive disease by the arrival of immune checkpoint inhibitors added to BCG
New Drugs, New Standards: What's Changing in Gastroesophageal Cancer Treatment
By Allan Pereira, MD, PhD
Gastroesophageal cancers (encompassing adenocarcinomas and squamous cell carcinomas of the esophagus and stomach, including gastroesophageal junction tumors) have seen more treatment advances in the past two years than in the preceding decade.
New Drugs, New Standards: What's Changing in Gastroesophageal Cancer Treatment
By Allan Pereira, MD, PhD
Gastroesophageal cancers (encompassing adenocarcinomas and squamous cell carcinomas of the esophagus and stomach, including gastroesophageal junction tumors) have seen more treatment advances in the past two years than in the preceding decade.
New Drugs, New Standards: What's Changing in Gastroesophageal Cancer Treatment
By Allan Pereira, MD, PhD
Gastroesophageal cancers (encompassing adenocarcinomas and squamous cell carcinomas of the esophagus and stomach, including gastroesophageal junction tumors) have seen more treatment advances in the past two years than in the preceding decade.
Upper GI Cancers at ASCO 2026: A New HER2-Positive Standard, a Negative Dual-IO Trial, Signals From Asia
By Dr. Ronan Hsieh
Upper GI cancers remain among the most lethal malignancies worldwide, and the treatment landscape has been evolving rapidly since the approvals of trastuzumab in HER2-positive disease and checkpoint inhibitors across the HER2-negative population.
Upper GI Cancers at ASCO 2026: A New HER2-Positive Standard, a Negative Dual-IO Trial, Signals From Asia
By Dr. Ronan Hsieh
Upper GI cancers remain among the most lethal malignancies worldwide, and the treatment landscape has been evolving rapidly since the approvals of trastuzumab in HER2-positive disease and checkpoint inhibitors across the HER2-negative population.
Upper GI Cancers at ASCO 2026: A New HER2-Positive Standard, a Negative Dual-IO Trial, Signals From Asia
By Dr. Ronan Hsieh
Upper GI cancers remain among the most lethal malignancies worldwide, and the treatment landscape has been evolving rapidly since the approvals of trastuzumab in HER2-positive disease and checkpoint inhibitors across the HER2-negative population.
HCC and Pancreatic Cancer at ASCO 2026: TACE Combinations in Liver Cancer, Daraxonrasib's New Standard
By Rachael A. Safyan, MD
ASCO 2026 brought two late-breaking presentations that are reshaping the treatment of hepatocellular carcinoma and pancreatic cancer.
HCC and Pancreatic Cancer at ASCO 2026: TACE Combinations in Liver Cancer, Daraxonrasib's New Standard
By Rachael A. Safyan, MD
ASCO 2026 brought two late-breaking presentations that are reshaping the treatment of hepatocellular carcinoma and pancreatic cancer.
HCC and Pancreatic Cancer at ASCO 2026: TACE Combinations in Liver Cancer, Daraxonrasib's New Standard
By Rachael A. Safyan, MD
ASCO 2026 brought two late-breaking presentations that are reshaping the treatment of hepatocellular carcinoma and pancreatic cancer.
Colorectal Cancer at ASCO 2026: Stopping Immunotherapy, BRAF-Targeted Therapy, and Exercise's Role
By Stacey A. Cohen, MD
Before discussing any of the specific advances from ASCO 2026, the single most important principle in colorectal cancer is straightforward: test all patients for microsatellite instability (MSI).
Colorectal Cancer at ASCO 2026: Stopping Immunotherapy, BRAF-Targeted Therapy, and Exercise's Role
By Stacey A. Cohen, MD
Before discussing any of the specific advances from ASCO 2026, the single most important principle in colorectal cancer is straightforward: test all patients for microsatellite instability (MSI).
Colorectal Cancer at ASCO 2026: Stopping Immunotherapy, BRAF-Targeted Therapy, and Exercise's Role
By Stacey A. Cohen, MD
Before discussing any of the specific advances from ASCO 2026, the single most important principle in colorectal cancer is straightforward: test all patients for microsatellite instability (MSI).
Prostate Cancer at ASCO 2026: Perioperative Intensification, Earlier PARP Inhibitors, and De-escalation
By Alexandra Sokolova, MD
ASCO 2026 brought multiple practice-influencing trials in prostate cancer spanning localized high-risk disease, metastatic hormone-sensitive disease, and de-escalation for exceptional responders.
Prostate Cancer at ASCO 2026: Perioperative Intensification, Earlier PARP Inhibitors, and De-escalation
By Alexandra Sokolova, MD
ASCO 2026 brought multiple practice-influencing trials in prostate cancer spanning localized high-risk disease, metastatic hormone-sensitive disease, and de-escalation for exceptional responders.
Prostate Cancer at ASCO 2026: Perioperative Intensification, Earlier PARP Inhibitors, and De-escalation
By Alexandra Sokolova, MD
ASCO 2026 brought multiple practice-influencing trials in prostate cancer spanning localized high-risk disease, metastatic hormone-sensitive disease, and de-escalation for exceptional responders.
Cellular Therapies for Multiple Myeloma Part II: CAR-T Toxicities for the Community Oncologist
By Aimaz Afrough, MD; Samer Al Hadidi, MD, MS; Sean Taasan, MD; Larry D Anderson Jr, MD, PhD
While ide-cel and cilta-cel are generally considered safe and have remarkable therapeutic impact for relapsed/refractory myeloma, both agents carry a broad and clinically significant toxicity burden that practitioners must recognize and actively surveil.
Cellular Therapies for Multiple Myeloma Part II: CAR-T Toxicities for the Community Oncologist
By Aimaz Afrough, MD; Samer Al Hadidi, MD, MS; Sean Taasan, MD; Larry D Anderson Jr, MD, PhD
While ide-cel and cilta-cel are generally considered safe and have remarkable therapeutic impact for relapsed/refractory myeloma, both agents carry a broad and clinically significant toxicity burden that practitioners must recognize and actively surveil.
Cellular Therapies for Multiple Myeloma Part II: CAR-T Toxicities for the Community Oncologist
By Aimaz Afrough, MD; Samer Al Hadidi, MD, MS; Sean Taasan, MD; Larry D Anderson Jr, MD, PhD
While ide-cel and cilta-cel are generally considered safe and have remarkable therapeutic impact for relapsed/refractory myeloma, both agents carry a broad and clinically significant toxicity burden that practitioners must recognize and actively surveil.
Cellular Therapies for Multiple Myeloma Part I: A CAR-T Primer for the Community Oncologist
By Aimaz Afrough, MD; Samer Al Hadidi, MD, MS; Sean Taasan, MD; Larry D Anderson Jr, MD, PhD
Ide-cel was the first anti-BCMA CAR-T product approved by the FDA in March 2021, employing a single anti-BCMA single-chain variable fragment.
Cellular Therapies for Multiple Myeloma Part I: A CAR-T Primer for the Community Oncologist
By Aimaz Afrough, MD; Samer Al Hadidi, MD, MS; Sean Taasan, MD; Larry D Anderson Jr, MD, PhD
Ide-cel was the first anti-BCMA CAR-T product approved by the FDA in March 2021, employing a single anti-BCMA single-chain variable fragment.
Cellular Therapies for Multiple Myeloma Part I: A CAR-T Primer for the Community Oncologist
By Aimaz Afrough, MD; Samer Al Hadidi, MD, MS; Sean Taasan, MD; Larry D Anderson Jr, MD, PhD
Ide-cel was the first anti-BCMA CAR-T product approved by the FDA in March 2021, employing a single anti-BCMA single-chain variable fragment.